Cargando…

Single drug biomarker prediction for ER− breast cancer outcome from chemotherapy

ER-negative breast cancer includes most aggressive subtypes of breast cancer such as triple negative (TN) breast cancer. Excluded from hormonal and targeted therapies effectively used for other subtypes of breast cancer, standard chemotherapy is one of the primary treatment options for these patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yong-Zi, Kim, Youngchul, Soliman, Hatem H, Ying, GuoGuang, Lee, Jae K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920016/ https://www.ncbi.nlm.nih.gov/pubmed/29599124 http://dx.doi.org/10.1530/ERC-17-0495

Ejemplares similares

CONCORD biomarker prediction for novel drug introduction to different cancer types
por: Kim, Youngchul, et al.
Publicado: (2017)

Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance
por: Ferriss, J. Stuart, et al.
Publicado: (2012)

Retrospective Analysis of Survival Improvement by Molecular Biomarker-Based Personalized Chemotherapy for Recurrent Ovarian Cancer
por: Kim, Youngchul, et al.
Publicado: (2014)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

SUMOhydro: A Novel Method for the Prediction of Sumoylation Sites Based on Hydrophobic Properties
por: Chen, Yong-Zi, et al.
Publicado: (2012)

MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer
por: Milevskiy, Michael J. G., et al.
Publicado: (2019)

A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy
por: Chen, Yanhua, et al.
Publicado: (2020)

Bioinformatics Analysis of Expression and Alterations of BARD1 in Breast Cancer
por: Chen, Yong-Zi, et al.
Publicado: (2019)

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
por: Gao, Tian, et al.
Publicado: (2014)

A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy
por: Shen, Kui, et al.
Publicado: (2012)

Screening of biomarkers for prediction of response to and prognosis after chemotherapy for breast cancers
por: Bing, Feng, et al.
Publicado: (2016)

FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer
por: Xie, Qin, et al.
Publicado: (2020)

An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer
por: Zhou, Xin, et al.
Publicado: (2014)

Gene Expression-Based Predictive Markers for Paclitaxel Treatment in ER+ and ER− Breast Cancer
por: Feng, Xiaowen, et al.
Publicado: (2019)

Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay
por: Soliman, Hatem, et al.
Publicado: (2019)

Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer
por: Moon, Hyeong-Gon, et al.
Publicado: (2012)

Kinase–substrate Edge Biomarkers Provide a More Accurate Prognostic Prediction in ER-negative Breast Cancer
por: Sun, Yidi, et al.
Publicado: (2020)

On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer
por: Bownes, Richard J., et al.
Publicado: (2019)

FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction
por: Liu, Shuo, et al.
Publicado: (2020)

Methylome Variation Predicts Exemestane Resistance in Advanced ER(+) Breast Cancer
por: Liu, Xiao-ran, et al.
Publicado: (2020)

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53
por: Millar, E K A, et al.
Publicado: (2011)

Distinct Genes Related to Drug Response Identified in ER Positive and ER Negative Breast Cancer Cell Lines
por: Shen, Kui, et al.
Publicado: (2012)

Epigenetic biomarker screening by FLIM-FRET for combination therapy in ER+ breast cancer
por: Liu, Wenjie, et al.
Publicado: (2019)

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy
por: Al-Mahayri, Zeina N., et al.
Publicado: (2020)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma
por: Shen, Wei-Wei, et al.
Publicado: (2020)

FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
por: Xing, Mingyou, et al.
Publicado: (2019)

Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer
por: Todorova, Valentina K., et al.
Publicado: (2022)

Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Zheng, Yi-Zi, et al.
Publicado: (2022)

Prediction of neoadjuvant chemotherapy response using diffuse optical spectroscopy in breast cancer
por: Yu, Ying-hua, et al.
Publicado: (2017)

An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment
por: Tang, Jianing, et al.
Publicado: (2019)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
por: Cohen, Pascale A., et al.
Publicado: (2019)

The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients
por: Mazo, Claudia, et al.
Publicado: (2020)

ER-α36: a novel biomarker and potential therapeutic target in breast cancer
por: Su, Xingyun, et al.
Publicado: (2014)

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

YAP inhibits ERα and ER(+) breast cancer growth by disrupting a TEAD-ERα signaling axis
por: Li, Xu, et al.
Publicado: (2022)

CircPVT1 promotes ER‐positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS
por: Yi, Jia, et al.
Publicado: (2023)

Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience
por: Coiro, Saverio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q82ad74kgnfbh7nku3qj4l3bjp